DZD-1516 is under clinical development by Dizal Pharmaceutical and currently in Phase I for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer). According to GlobalData, Phase I drugs for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer) have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how DZD-1516’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

DZD-1516 overview

DZD-1516 is under development for the treatment of metastatic HER2 positive breast cancer and solid tumor. It is administered by oral route in the form of tablets. The drug acts by targeting tyrosine kinase type cell surface receptor HER2.

Dizal Pharmaceutical overview

Dizal Pharmaceutical (Dizal) is a biopharmaceutical company. It focuses on research, development, and commercialization of therapies to treat cancer and immunological diseases. The company’s lead product candidate ZEGFROVY, which is at marketing approval stage for treatment of solid tumors. Its product pipeline includes other drug programs such as JAUKPO to treat hematological malignancy, solid tumors, and immunological diseases; DZD8586 for treatment of hematological malignancy; and DZD2269 and DZD1516 to treat solid tumors. The company operates with additional facilities in Beijing, Wuxi, Chengdu, China. Dizal is headquartered in Shanghai, China.

For a complete picture of DZD-1516’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.